Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

OConnell Casey L.; Kropf Patricia L.; Punwani Nathan; Rogers Dan; Sposto Richard; Gronbaek Kirsten

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

【24h】

Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

机译：第二阶段I结果将瓜鹃阿替滨（DNA甲基转移酶抑制剂）与atezolizumab，免疫检查点抑制剂，复发或难治性髓细胞增生综合征或慢性骨髓细胞白血病患者组合的多中心临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
OConnell Casey L.; Kropf Patricia L.; Punwani Nathan; Rogers Dan; Sposto Richard; Gronbaek Kirsten;
展开▼
作者单位

Univ Southern Calif Keck Sch Med Los Angeles CA 90033 USA;

Fox Chase Canc Ctr 7701 Burholme Ave Philadelphia PA 19111 USA;

Univ Southern Calif Keck Sch Med Jane Anne Nohl Div Hematol Los Angeles CA 90033 USA;

Van Andel Res Inst Grand Rapids MI USA;

Childrens Hosp Los Angeles Pediat Los Angeles CA 90027 USA;

Copenhagen Univ Hosp Dept Hematol Rigshosp Copenhagen Denmark;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [J] . OConnell Casey L., Kropf Patricia L., Punwani Nathan, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：第二阶段I结果将瓜鹃阿替滨（DNA甲基转移酶抑制剂）与atezolizumab，免疫检查点抑制剂，复发或难治性髓细胞增生综合征或慢性骨髓细胞白血病患者组合的多中心临床试验
2. Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sezary syndrome: Interim results of a multicenter Phase 1 trial [J] . Querfeld Christiane, Thompson John A., Taylor Matthew, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：CD47阻断免疫检查点抑制剂TTI-621（SIRPAFC）的内部内注射诱导患者复发/难治性霉菌菌和Sezary综合征的抗肿瘤活性：多中心阶段1试验的中期结果
3. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia [J] . Yee Karen W. L., Chen Hsiao-Wei T., Hedley David W., Investigational new drugs. . 2016,第5期

机译：极光激酶抑制剂ENMD-2076在患有复发或难治性急性髓细胞性白血病或慢性粒细胞性白血病的患者中进行的I期试验
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. Phase I trial of SAR103168 a novel multi-kinase inhibitor in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes [O] . Gail J. Roboz, H. Jean Khoury, Elias Jabbour, -1

机译：新型的多激酶抑制剂SAR103168在难治性/复发性急性白血病或高危骨髓增生异常综合症患者中的I期试验
6. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE) [O] . Simon J. Crabb, Sarah Danson, James W.F. Catto, 2021

机译：DNA甲基转移酶抑制剂瓜达汀的阶段I试六符与顺铂和吉西他滨联合固体恶性肿瘤，包括尿路上皮癌（尖顶）

Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

著录项

相似文献

相关主题

期刊订阅